OcuTerra Therapeutics

0 followers


OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity

Industries

Employees

1-10

Links

Org chart

David J. Tanzer
Chief Medical Officer
Susannah Sinozich
Senior Clinical Program Director